

CLAIMS

What is claimed is:

1. A method of treating a patient for sleep disorders
5 comprising administering to said patient a therapeutically effective amount of 2-cyano-10-(2-methyl-3-(methylamino)propyl)phenothiazine (I) or a pharmaceutically acceptable salt thereof.
- 10 2. The method as set forth in claim 1 wherein said sleep disorder is insomnia.
- 15 3. The method as set forth in claim 1 wherein said sleep disorder is primary insomnia.
4. The method as set forth in claim 1 wherein said sleep disorder is insomnia related to another mental disorder.
- 20 5. The method as set forth in claim 1 wherein said sleep disorder is obstructive sleep apnea.
6. The method as set forth in claim 1 wherein 2-cyano-10-(2-methyl-3-(methylamino)propyl)-
25 phenothiazine (I) or a pharmaceutically acceptable salt thereof is present in an amount of from about 10 mg to about 300 mg.

7. The method as set forth in claim 1 wherein 2-cyano-10-(2-methyl-3-(methylamino)propyl)-phenothiazine (I) or a pharmaceutically acceptable salt thereof is administered orally or
5 parenterally.
8. A method of treating a patient suffering from a disease selected from the group consisting of anxiety disorder, mood disorder, mixed anxiety-depression disorder, acute and chronic psychotic state, addiction to and withdrawal from a substance, extrapyramidal event induced by an antipsychotic and a symptomatic dimension during acute or chronic psychotic state, comprising
10 administering to said patient a therapeutically effective amount of 2-cyano-10-(2-methyl-3-(methylamino)propyl)phenothiazine (I) or a pharmaceutically acceptable salt thereof.
15
- 20 9. The method as set forth in claim 8 wherein said disease is anxiety disorder.
10. The method as set forth in claim 8 wherein said disease is mood disorder.
25
11. The method as set forth in claim 8 wherein said

disease is mixed anxiety-depression disorder.

12. The method as set forth in claim 8 wherein said disease is an acute and chronic psychotic state.

5

13. The method as set forth in claim 8 wherein said disease is addiction to and withdrawal from a substance.

10 14. The method as set forth in claim 8 wherein said disease is an extrapyramidal event induced by an antipsychotic.

15. The method as set forth in claim 8 wherein said disease is a symptomatic dimension during acute or chronic psychotic state as monotherapy or in combination with another antipsychotic.

16. The method as set forth in claim 8 wherein 2-cyano-10-(2-methyl-3-(methylamino)propyl)-phenothiazine (I) or a pharmaceutically acceptable salt thereof is present in an amount of from about 10 mg to about 300 mg.

25 17. The method as set forth in claim 8 wherein 2-cyano-10-(2-methyl-3-(methylamino)propyl)-

phenothiazine (I) or a pharmaceutically acceptable salt thereof is administered orally or parenterally.

5 18. A method for preparing a medicament comprising mixing a therapeutically effective amount of 2-cyano-10-(2-methyl-3-(methylamino)-propyl)phenothiazine or a pharmaceutically acceptable salt thereof with one or more 10 compatible and pharmaceutically acceptable diluents or adjuvants.

19. The method as set forth in claim 18 wherein 2-cyano-10-(2-methyl-3-(methylamino)propyl)-15 phenothiazine (I) or a pharmaceutically acceptable salt thereof is present in an amount of from about 10 mg to about 300 mg.

20. The method as set forth in claim 18 wherein the 20 medicament further includes an antipsychotic.